Monaghan Medical Corporation (MMC), headquartered in Plattsburgh, New York, offers leading aerosol drug delivery devices and respiratory management products including the AEROECLIPSE® BAN, AEROCHAMBER® Brand of VHC and the AEROBIKA® OPEP device exclusively in the United States. MMC focuses on developing cost-efficient, outcome-based solutions for its customers.
LEARN MORE >>AEROBIKA® OPEP Device Advantage
- Reduces COPD readmissions by 28% in the critical 30-day period
- Trend toward shorter length of stay
- Reduced use of oral corticosteroids and antibiotic treatments
- Improves lung function and ventilation in COPD
- Reduces post-operative readmissions by 39% in the critical 30-day period
- Use of the device resulted in shorter length of stay and significantly lower costs
- Cost effective addition to standard of care
Hospital Cost Savings Estimate
In peer-reviewed published studies, the AEROBIKA® Oscillating Positive Expiratory Pressure (OPEP) device has been shown to support cost savings in both COPD Exacerbation and Post-Operative Recovery in a hospital setting. Use the calculator to the right to estimate the cost savings your facility could achieve by implementing the AEROBIKA® OPEP device to your existing standard of care.
Improved quality of life
by design.